This trial is active not recruiting!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Severe Sepsis or Coagulopathy
and you are
over 18
years old
3
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

The purpose of the study is to evaluate if ART-123 given to patients who have severe sepsis can decrease mortality.

Provided treatments

  • Drug: ART-123
  • Drug: Placebo
Tris trial is registered with FDA with number: NCT01598831. The sponsor of the trial is Asahi Kasei Pharma America Corporation and it is looking for 814 volunteers for the current phase.
Official trial title:
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of ART-123 in Subjects With Severe Sepsis and Coagulopathy.